TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01453881

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spacer
Description: Beclomethasone/Formoterol 100/6mcg pMDI 2 puffs two times/day with the aid of a Valved Holding Chamber - VORTEX

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: Beclomethasone/Formoterol 100/6mcg pMDI 2 puffs two times/day without the aid of a Valved Holding Chamber - VORTEX
Study: NCT05595538

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multiple doses of anti-SARS-CoV-2 Convalescent Plasma
Description: SARS-CoV-2 Convalescent Plasma(1-2 units; \~300-600 mL with the presence of IgG anti-SARS-CoV-2.
Study: NCT03496753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Led Therapy
Description: The following will be the phototherapeutic parameters: total spot area: 1.44 cm²; continuous emission mode; output power: 10 mW; infrared wavelength (880 to 904 nm); fluence: 4 J/cm²; and application time: 10 minutes/session. Sessions will be held three times a week on alternating days for six consecutive weeks, totaling 18 sessions.
Study: NCT02047669

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biopsychosocial

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reference
Study: NCT02960282

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of fecal specimens

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04550026

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HTP inhalation
Description: Sham inhalation for 30 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HTP inhalation
Description: Sham inhalation for 30 minutes
Study: NCT04472728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIO101
Description: BIO101 capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsules
Study: NCT06237023

Intervention type: OTHER
Group type: OTHER
Intervention: epidemyolojical
Description: The aim of the study is to compare emergency orthopedic trauma admissions between the pre-pandemic and pandemic periods, and to identify changes in the epidemiology of orthopedic trauma.

Intervention type: OTHER
Group type: OTHER
Intervention: epidemyolojical
Description: The aim of the study is to compare emergency orthopedic trauma admissions between the pre-pandemic and pandemic periods, and to identify changes in the epidemiology of orthopedic trauma.
Study: NCT02992574

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Post Mastectomy Radiation therapy
Description: Post mastectomy radiotherapy to the chest wall and ipsilateral supra-clavicular fossa to a dose of 40 Gy in 15 fractions over 3 weeks
Study: NCT04598542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorecivivint (LOR)
Description: 0.07 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorecivivint (LOR)
Description: 0.07 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TA)
Description: 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TA)
Description: 40 mg
Study: NCT01576640

Intervention type: DRUG
Group type: OTHER
Intervention: NRT
Description: Participants received nicotine replacement therapy in the form of nicotine gum/lozenge and nicotine patch

Intervention type: DRUG
Group type: OTHER
Intervention: Bupropion SR 150mg bid
Description: Subjects were given bupropion SR 150 mg bid throughout the course of the study.
Study: NCT01942746

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Blueberry Juice S2
Description: Blueberry Juice S2 was commercially prepared single strength blueberry juice composed of a 50:50 blend of Rubel (Vaccinium corymbosum L.) and Tifblue (Vaccinium ashei Reade) cultivars. Colorimetric analysis showed that S2 juice contained 6.04 (SD=0.20) mg anthocyanins (C3G) eq/g dry mass.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Blueberry Capsules S2
Description: Commercially prepared single strength blueberry juice composed of a 50:50 blend of Rubel (Vaccinium corymbosum L.) and Tifblue (Vaccinium ashei Reade) cultivars was freeze dried then powdered and encapsulated in gelatin capsules. Colorimetric analysis indicated an anthocyanin concentration in the powder of 2.37(SD=0.18) mg C3G eq per capsule.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule S2
Description: Placebo Capsule S2 (containing no anthocyanins) were prepared by freeze drying red beets and grinding them to fine powder before encapsulating in gelatine capsules. Red beets do not contain anthocyanins.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Juice L1
Description: Placebo juice was prepared from water, sugars, citric acid, sodium citrate, and artificial colors and flavours, then pasteurized. The placebo juice contains no anthocyanins.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Blueberry Juice L1
Description: Blueberry Juice L1 was commercially prepared single strength blueberry juice composed of a 50:50 blend of Rubel (Vaccinium corymbosum L.) and Tifblue (Vaccinium ashei Reade) cultivars. Colorimetric analysis showed that L1 juice contained 6.83 (SD=0.20) mg cyanidin-3-glucoside equivalents (C3GE)/g dry mass at the start of the study, declining to 5.52 (SD=0.09) mg C3GE/g dry mass after 3 months refrigerated storage.
Study: NCT01518972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin
Description: Form: Prazosin will be taken orally, in the form of pills.~Dosing: 9 AM, 3 PM, 9 PM~Days 1-2: 0 mg, 0 mg, 1 mg~Days 3-4: 1 mg, 1 mg, 1 mg~Days 5-7: 2 mg, 2 mg, 2 mg~Day 8-10: 2 mg, 2 mg, 6 mg~Day 11-14: 4 mg, 4 mg, 6 mg~Day 15-84: 4 mg, 4 mg, 8 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo medication
Description: Form: Placebo will be taken orally, in the form of pills.~Dosing: 9 AM, 3 PM, 9 PM~Days 1-2: 0 mg, 0 mg, 1 mg~Days 3-4: 1 mg, 1 mg, 1 mg~Days 5-7: 2 mg, 2 mg, 2 mg~Day 8-10: 2 mg, 2 mg, 6 mg~Day 11-14: 4 mg, 4 mg, 6 mg~Day 15-84: 4 mg, 4 mg, 8 mg
Study: NCT02042365

Intervention type: PROCEDURE
Intervention: ERAS (Enhanced recovery after surgery)
Study: NCT01576640

Intervention type: OTHER
Group type: OTHER
Intervention: Relapse Prevention-Oriented Cognitive Behavioral Therapy
Description: Subjects received relapse-prevention oriented cognitive behavioral therapy that was held weekly for 4 weeks, biweekly for 8 weeks, then monthly for 36 weeks.
Study: NCT04272593

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EMG-Pattern Recognition Controller
Description: Using an electromyographic (EMG)-based pattern recognition controller to move an upper limb prosthetic device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMG-Pattern Recognition Controller
Description: Using an electromyographic (EMG)-based pattern recognition controller to move an upper limb prosthetic device.
Study: NCT03585140

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal diet
Description: The energy consumption of each of the participants will be calculated, using the Mifflin-St Jeor formula. Each participant will receive a standard menu of 6 days according to their metabolic requirements and a list of equivalent foods. The distribution of macronutrients will be: 45% carbohydrates, 30% lipids and 25% proteins.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low glycemic diet
Description: The energy consumption of each of the participants will be calculated, using the Mifflin-St Jeor formula. Each participant will receive a standard menu of 6 days according to their metabolic requirements and a list of equivalent foods. A list of foods classified as having low index and glycemic load was used according to the mexican equivalent food system. The distribution of macronutrients will be: 45% carbohydrates, 30% lipids and 25% proteins. Milk and vitamin supplements will be eliminated from the diet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% Gel
Description: Adapalene 0.1% gel daily at night for 12 weeks, applied on the face, chest and back.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adapalene 0.1% Gel
Description: Adapalene 0.1% gel daily at night for 12 weeks, applied on the face, chest and back.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline 100 mg per day orally, before breakfast

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Doxycycline 100 mg per day orally, before breakfast
Study: NCT03390140

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ReInventing Yourself after SCI structured group CBT
Description: ReInventing Yourself after SCI intervention integrates positive psychotherapy concepts into structured group cognitive behavioral therapy (CBT) to develop optimistic self-efficacy beliefs, thereby strengthening resilience to emotional distress, enhancing a sense of well-being and promoting a more active lifestyle. The intervention consists of six weekly two-hour facilitator-led sessions that include didactic presentations of eight core skills and related experiential exercises with extensive group discussion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ReInventing Yourself after SCI study-specific workbook
Description: A study-specific workbook that incorporates positive psychotherapy concepts to develop optimistic self-efficacy beliefs, thereby strengthening resilience to emotional distress, enhancing a sense of well-being and promoting a more active lifestyle.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ReInventing Yourself after SCI study-specific workbook
Description: A study-specific workbook that incorporates positive psychotherapy concepts to develop optimistic self-efficacy beliefs, thereby strengthening resilience to emotional distress, enhancing a sense of well-being and promoting a more active lifestyle.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ReInventing Yourself after SCI YouTube videos
Description: YouTube videos containing the content of the ReInventing Yourself after SCI structured group CBT sessions
Study: NCT03983499

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Special Intervention
Description: The components of the Special Intervention (SI) integrated design are: 1) Co-location of the clinical team; 2) Shared medical plan; 3) Clinical visits with a medical provider for management of chronic medical conditions; 4) Visits with behavioral health provider for management of psychosocial chronic conditions; 5) Care coordination; 6) Six group-health education classes and two booster sessions led by a promotora. Participants in the SI arm meet with the integrated care team in the context of a regular medical visit primarily to focus on clinical/biological aspects of the chronic medical conditions (diabetes, dyslipidemia, hypertension, obesity, etc.)
Study: NCT03719235

Intervention type: OTHER
Group type: OTHER
Intervention: CBCT
Description: ultra-low dose CBCT
Study: NCT02197377

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group LMA Unique™
Description: The supraglottic airway devices were deflated fully before insertion. After placement an effective airway was defined as the presence of normal thoracoabdominal movement and a square-wave end-tidal carbon dioxide trace.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group LMA Supreme™
Description: The supraglottic airway devices were deflated fully before insertion.The supraglottic airway devices were deflated fully before insertion. After placement an effective airway was defined as the presence of normal thoracoabdominal movement and a square-wave end-tidal carbon dioxide trace.
Study: NCT02076165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and the Behavioral Changes to Treat Insomnia
Description: Participants attended 5 individual sessions incorporating behavioral treatment components plus acceptance and commitment therapy (ACT) with a trained instructor.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy for insomnia
Description: Participants attended 5 individual sessions incorporating behavioral and cognitive therapy components with a trained instructor.
Study: NCT01135732

Intervention type: PROCEDURE
Intervention: brush cytology
Description: brush cytology during ERCP

Intervention type: PROCEDURE
Intervention: brush cytology
Description: brush cytology during ERCP
Study: NCT03893045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferumoxytol
Description: Each 20 mL single-use vial contains 17 mL of ferumoxytol that consists of iron at a concentration of 30 mg Fe/mL, coated with polyglucose sorbitol carboxymethylether and formulated with mannitol, at a concentration of 44 mg/mL, in a black to reddish brown sterile, aqueous, colloidal, isotonic solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron sucrose
Description: Each mL contains 20 mg of elemental iron as iron sucrose in water for injection. The 5 mL single-use vial contains 100 mg of iron per 5 mL. The drug product contains approximately 30% sucrose (300 mg/mL).
Study: NCT03625531

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Women in both personalized and fixed acupuncture groups will receive acupuncture treatment three times a week. Acupuncture treatment will start on day 3 after a spontaneous period or after a withdrawal bleeding following progestin. Each treatment session will last for 30-60 minutes, with a maximum of 48 treatment sessions over 16 weeks. If they become pregnant, the acupuncture treatment will be stopped. For personalized and fixed acupuncture group, credibility and expectancy questionnaires will be completed on the third acupuncture treatment and the last acupuncture treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Women in both personalized and fixed acupuncture groups will receive acupuncture treatment three times a week. Acupuncture treatment will start on day 3 after a spontaneous period or after a withdrawal bleeding following progestin. Each treatment session will last for 30-60 minutes, with a maximum of 48 treatment sessions over 16 weeks. If they become pregnant, the acupuncture treatment will be stopped. For personalized and fixed acupuncture group, credibility and expectancy questionnaires will be completed on the third acupuncture treatment and the last acupuncture treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Letrozole will be started on day 3 to day 7 of the spontaneous period or a withdrawal bleeding following progestin. If there is response with ovulation, this dose will be maintained. In those with no ovulatory response, letrozole tablets of the next ovulation cycle will be take on the day 28 of the menstrual cycle and the letrozole dose will be increased to 5 mg (2 pills) a day for 5 days. If there is still no response, the dose will be increased to 7.5 mg per day for 5 days in the next cycle. The maximum daily dose of letrozole will be 7.5 mg (3 pills) daily for five days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo letrozole
Description: Placebo letrozole will be given in the same way as letrozole. Women will receive 1 tablet a day of placebo letrozole from the day 3 to day 7 of the menstrual cycle and placebo letrozole dose will be increased 2 tablets a day in the next cycle if there is no response. The maximum daily dose of placebo letrozole will be 3 tablets daily for five days.
Study: NCT03017209

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Locally-prepared bar
Description: School children in first grade will receive their supplement 5 days a week in the morning before school starts. Younger children will receive the supplement 5 days a week in the morning at the community health center, distributed by community health workers. The teachers and community health workers will record amount of supplement consumption daily during the study, and will report the information weekly to the local research team throughout the intervention period.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: USAID Corn Soy Blend Plus
Description: School children in first grade will receive their supplement 5 days a week in the morning before school starts. Younger children will receive the supplement 5 days a week in the morning at the community health center, distributed by community health workers. The teachers and community health workers will record amount of supplement consumption daily during the study, and will report the information weekly to the local research team throughout the intervention period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: School children in first grade will receive their supplement 5 days a week in the morning before school starts. Younger children will receive the supplement 5 days a week in the morning at the community health center, distributed by community health workers. The teachers and community health workers will record amount of supplement consumption daily during the study, and will report the information weekly to the local research team throughout the intervention period.
Study: NCT03644290

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Five sessions of semantic strategy training and face-name association training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Condition
Description: Five sessions of active control information and education
Study: NCT03157362

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Near Non-Social
Description: Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience a virtual environment that reproduces the room in which they are seated.
Study: NCT05037604

Intervention type: OTHER
Intervention: Questionnaire about associated factors
Description: Questionnaire about age, prolonged sun exposure, intake of anticoagulants / antiplatelets, intake of oral steroids, chronic kidney disease. Maternal age\> 40 years in their last child , time of lactation per pregnancy and cumulative time of lactation. Age of the first pregnancy and age of menopause onset.

Intervention type: OTHER
Intervention: Questionnaire about associated factors
Description: Questionnaire about age, prolonged sun exposure, intake of anticoagulants / antiplatelets, intake of oral steroids, chronic kidney disease. Maternal age\> 40 years in their last child , time of lactation per pregnancy and cumulative time of lactation. Age of the first pregnancy and age of menopause onset.
Study: NCT02006771

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Southern Chinese meal
Description: White rice (1 bowl), stir fried choi sum (0.5 bowl) and stir fried lean pork (0.5 bowl) cooked with maize oil

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Northern Chinese meal
Description: Noodles (1 bowl) and shredded pork with sweet bean sauce (0.5 bowl) cooked with blend oil

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: American meal
Description: Hamburger with cheese (1 piece), French fries (117 g) cooked with canola blend oil and Coca-cola classic (21 fluid ounces)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: South Indian meal
Description: Basmati rice (1 bowl), chicken curry dish (0.5 bowl), dry vegetable dish (i.e. green beans mixed with herbs) (0.5 bowl), yogurt made with milk powder mainly (0.5 bowl), pickle made with lemon, salt, chilli powder, Asafoetida and vegetable based oil (1 tablespoon)
Study: NCT01371461

Intervention type: DRUG
Intervention: Paroxetine
Study: NCT02537041

Intervention type: PROCEDURE
Group type: OTHER
Intervention: elastography function ShearWave Imaging
Description: non-invasive assessment of myocardial stiffness by elastography

Intervention type: PROCEDURE
Group type: OTHER
Intervention: elastography function ShearWave Imaging
Description: non-invasive assessment of myocardial stiffness by elastography

Intervention type: PROCEDURE
Group type: OTHER
Intervention: elastography function ShearWave Imaging
Description: non-invasive assessment of myocardial stiffness by elastography

Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI

Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI

Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI
Study: NCT04402047

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: We will apply Ashi points, Ex-UE9, SI3, and TE5. Sterile needles (0.3mm× 40mm) and SDZ-V EA apparatus will be utilized. Acupuncturists will insert needles perpendicularly into Ashi points for approximately 2-3mm until they pierce into the bone surface; acupuncturists will insert needles horizontally into Baxie points towards the wrist with a depth of 5-10mm; and acupuncturists will insert needles perpendicularly into SI3 and TE5 for approximately 5-10mm. All needles except Ashi points will be manually manipulated to achieve De qi. The needles at Baxie 1 and Baxie 4 will be connected using alligator clips from the EA apparatus. The electrical stimulation will last for 30 minutes with a continuous wave of 10 Hz and a fixed current intensity of 0.5 to 2 mA. All the needles will be retained for 30 minutes. Participants will undergo EA treatment three times per week for a total of 12 sessions in four consecutive weeks. If bilateral hands were affected, both sides will be treated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical diclofenac sodium gel
Description: The gel will be gently rubbed over the affected joints without excessive joint movement four times per day for 4 weeks and will be asked not to wash hands for one hour after application. Each hand treatment will be used in identical dispensing doses of gel (4 cm strip, approximately 2g, which was judged sufficient for approximately half the surface of each hand (200 cm2)). Dosing times should be distributed evenly over waking hours.If bilateral hands were affected, both sides will be treated.
Study: NCT04004949

Intervention type: OTHER
Intervention: Assessment of scapular balance angle and upper extremity sensorimotor function
Description: The patients were diagnosed with the Lateral scapular slide test using Palpation meter (PALM) device, Fugl-Meyer upper extremity (FMUE) Scale scores \& scapular balance angle test (SBA).

Intervention type: OTHER
Intervention: Assessment of scapular balance angle and upper extremity sensorimotor function
Description: The patients were diagnosed with the Lateral scapular slide test using Palpation meter (PALM) device, Fugl-Meyer upper extremity (FMUE) Scale scores \& scapular balance angle test (SBA).
Study: NCT01907620

Intervention type: OTHER
Group type: OTHER
Intervention: blood sample

Intervention type: OTHER
Group type: OTHER
Intervention: blood sample